 |
 Video: What is a Stock Split?
|
|
|
| Gain Therapeutics is a biotechnology company developing small molecule therapeutics to treat diseases across, several therapeutics areas, including, central nervous system disorders, lysosomal storage disorders, metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. Co.'s primary product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and increase of dopamine levels and improved locomotor function in animal models. According to our Gain Therapeutics stock split history records, Gain Therapeutics has had 0 splits. | |
|
Gain Therapeutics (GANX) has 0 splits in our Gain Therapeutics stock split history database.
Looking at the Gain Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Gain Therapeutics shares, starting with a $10,000 purchase of GANX, presented on a split-history-adjusted basis factoring in the complete Gain Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
03/22/2021 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$13.20 |
|
| End price/share: |
$3.03 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-77.05% |
|
| Average Annual Total Return: |
-37.81% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$2,295.18 |
|
| Years: |
3.10 |
|
|
|
|
|
